Cello has issued a positive update on H1/19E trading, showing that Cello Health has continued its strong, organic momentum at higher margins. Meanwhile, Cello Signal's trading has been stable, as it increasingly takes on a healthcare focus. Today's update provides evidence that conditions in Cello's primary US healthcare market remain favourable. The company continues to identify accretive acquisitions in this space, which we believe could be a catalyst to the shares, currently trading on a mode ....
18 Jul 2019
Cenkos: Cello Group Plc - Organic momentum continues into 2019

